Fosun Pharma Subsidiary Launches Phase III Trial of Complement Inhibitor FXS6837 for PNH

Bulletin Express11-04

Shanghai Fosun Pharmaceutical Industrial Development Company Limited, a subsidiary of Fosun Pharma, has begun a Phase III clinical study of FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in mainland China.

FXS6837 is an internally developed small-molecule inhibitor targeting the complement system and holds independent intellectual property rights within the Fosun Pharma group. Beyond PNH, the molecule is also undergoing a Phase IIb trial for glomerular diseases with abnormal complement activation, including IgA nephropathy.

As of September 2026, cumulative research and development spending on FXS6837 totals approximately RMB199.00 million (unaudited).

Market data from IQVIA CHPA show that sales of leading PNH therapies in mainland China reached around RMB295.00 million in 2025, underscoring the commercial potential of new treatment options.

FXS6837 must still complete clinical testing and obtain regulatory approval before commercial launch, and the development timeline remains subject to inherent clinical and regulatory uncertainties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment